Drugs / TCR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05905731 | Jun 2023 → Jun 2025 | chronic hepatitis B virus infection | Beijing 302 Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05905731 ↗ |
| Modality | Cell therapy | “Autologous T-cells Transfected With mRNA Encoding HBV-TCR T Cell Therapy” NCT05905731 ↗ |
| Route | Intravenous | “by IV infusion” NCT05905731 ↗ |